|Day Low/High||48.72 / 49.55|
|52 Wk Low/High||44.30 / 63.69|
The initial public offering of Hansoh Pharmaceutical Group made the Chinese couple Zhong Huijuan and Sun Piaoyang the richest in the nation.
Chinese authorities are auditing the books of 77 drugmakers, including three multinationals, they say were selected at random. Were they motivated by embarrassment over a college-admissions payment made by a Chinese pharmaceuticals' tycoon?
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
What happened to the business president? I think what happened is that the polls are showing that whatever the president is doing is working.
BMY is not 'out of the woods' yet, but aggressive traders could probe the long side here.
This is the first time I can ever recall when a president is so attuned to the market that he will bend to its wishes.
As usual, the stocks that bounce back first are the tech stocks with little Chinese exposure and the consumer packaged goods that just demonstrated good numbers.
Analyzing this year's stock draft contest and individual stock-picking vs. indexing.
The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.
Market is pretty much where it has been all day, nicely positive across the board. Biotech up nearly 2% on the day. Gilead Sciences, Inc. , and Celgene Corp. , are two large caps on the move for reasons we covered in previous posts. The Bristol-Myer...
We are currently in process of restoring my access that is blocking me from seeing or commenting on the Daily Diary. We hope to have the problem resolved soon. Our apologies while getting the issue resolved. The market is off to a solid start this F...
The biotech sector isn't for the faint of heart, but these two companies issued promising news this week.
David Tepper's Appaloosa LP renews calls for changes at the top.
Experts offer their top stock ideas in oncology detection and treatment.
Management commentary from CAT is key on Monday.
Replacing fear with pragmatism, that is our goal.
These themes are working despite the turmoil in Washington and slowing global growth.
Is it a retest based on the damage the Fed has already done, the result of a breakdown in trade talks or a sign of a slowing global economy?
The RMPIA is once again outpacing the S&P 500, Dow Jones Industrial Average and the Nasdaq Composite Index.
Deals that simply were unworkable four months ago because of price are now being done with alacrity.
One of pharma's biggest CEO's talks M&A action on the exchange.
The company is set to report earnings on Jan. 29, so traders have a couple of weeks to watch the action.
This is the kind of reversal that happens in a bull market.
The RMPIA index was up for the year, while the S&P 500, DJIA, Russell 2000 and Nasdaq all finished 2018 in the red.
It's probably no surprise that my picks for 2019 come from the biotech/biopharma space.
It's likely that investors will be closely watching the U.S.-China trade talks to see if the skies brighten longer term.
Pharma companies that have cash are looking at what has happened to this stock market and buying.